For the first time, a Publicly Traded U.S. Company Is Fully Aligning Its Treasury Strategy with Litecoin. MEI Pharma (NASDAQ: MEIP) has announced a $100 million investment plan to hold Litecoin (LTC) as a treasury reserve asset.
The $100 million deal is a private investment in public equity (PIPE), led by GSR, a major crypto capital markets firm. GSR will also act as MEI’s digital asset treasury manager and strategic advisor. MEI will sell about 29.2 million shares at $3.42 per share, with the deal expected to close around July 22, 2025.
Litecoin creator Charlie Lee will officially join MEI’s Board of Directors after the investment closes. He brings deep knowledge and credibility to the project. GSR will also appoint a representative to the board. The Litecoin Foundation, along with crypto-focused investors like ParaFi, CoinFund, HiveMind, and others, joined the round.
Charlie Lee said, “For 14 years, Litecoin has consistently delivered a stable, low-cost, and accessible network for millions and over a decade.” He also added that it’s already widely used for payments, cross-border transfers, and remittances. Litecoin ranks high in transaction volume on platforms like BitPay. This partnership brings its real-world utility into the hands of institutions for the first time.
Since launching Litecoin in 2011, Lee has been a key figure in crypto. He’s pushed important upgrades like SegWit (also later adopted by Bitcoin), added privacy features, and supported projects like the Lightning Network. His leadership has helped Litecoin stay relevant and innovative. At the time of writing, Litecoin (LTC) is trading at $103.91 with a 24-hour gain of 2.98%.
MEI Pharma is shifting its business direction as part of a bigger strategy review. The company sees this partnership with GSR and Litecoin as a way to bridge traditional finance and crypto innovation. MEI will use GSR’s help to manage LTC securely and efficiently as part of its new treasury strategy.
MEI’s stock has risen over 147% year-to-date, trading around $6.30, and has a market cap of almost $38 million. Although MEI Pharma is mainly known for its drug development, this major move into crypto signals a big shift in its business goals.
Also Read: Emirates Airlines and Dubai Duty Free to Accept Litecoin Payments
